Galera Therapeutics: Clinical stage biopharmaceutical company focusing on transforming radiotherapy in cancer. Lead asset GC4419 is a potent, highly selective small molecule dismutase mimetic being developed for severe oral mucositis, currently in Phase 3 with Breakthrough Therapy Designation. Topline results expected in 2H21. Top line results in Phase 1b/2a in second asset, GC4711 in pancreatic cancer expected in 2H20. GC4711 expected to initiate in Phase 1b/2a in lung cancer in 2H20.
Based in...
US - Middle Atlantic
Clinical Stage
Phase III, Phase l or ll, Pre-Clinical Stage
Disease Space
Immuno-Oncology, Oncology
Public, USA
Market Cap
100MM - 500MM
2 West Liberty Blvd
Suite 110
Malvern, Pennsylvania 19355
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Galera Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
NEA Management Co. 17.91 4,362,986 35.82 13F 6/30/20
Novo Holding A/S 13.99 3,409,021 27.99 13F 6/30/20
Sofinnova Ventures, Inc. 12.66 3,083,712 25.32 13F 6/30/20
Clarus Ventures LLC 6.89 1,678,984 13.78 13F 6/30/20
Adage Capital Partners GP LLC 6.20 1,509,500 12.39 13F 6/30/20
Adage Capital Management LP 5.22 1,300,000 10.67 Stakes 11/7/19
Tekla Capital Management LLC 4.28 1,041,845 8.55 13F 6/30/20
RA Capital Management LLC 3.39 825,118 6.77 13F 6/30/20
Rock Springs Capital Management LP 2.33 567,552 4.66 13F 6/30/20
Sphera Funds Management Ltd. 1.93 469,245 3.85 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.